Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone for locally advanced laryngeal & nasopharyngeal cancers: A retrospective study

Abstract

Background: One of the most common cancers all over the world is Head and Neck cancers, with higher mortality rates among developing countries. Squamous cell carcinomas (SCCs) represent more than 90%. SCCs arise commonly from the mucosal lining of the upper aerodigestive tract.
Objective: To Compare between Concurrent Chemoradiation following Neoadjuvant Chemotherapy versus Concurrent Chemoradiation alone in Locally Advanced Larynx & Nasopharynx Cancer (stage III or IVA,B) regarding efficacy, toxicity, progression free survival, disease free survival and organ preservation (in laryngeal cancer).
Methods: A Retrospective study was conducted to Compare between Concurrent Chemoradiation following Neoadjuvant Chemotherapy versus Concurrent Chemoradiation alone in Locally Advanced Larynx & Nasopharynx Cancer (stage III or IVA,B) in the Clinical Oncology Department, Suez Canal University Hospital, Ismailia, Egypt between 1/2017 & 12/2018, with follow up 2 years (from 1/2019 to 12/2020).
Results: Results of our study show a statistic significance in progression free survival in Concurrent chemoradiation following neoadjuvant chemotherapy compared with concurrent chemoradiation alone.
Conclusions: Neoadjuvant chemotherapy by TPF or PF is a wise choice in the locally advanced squamous cell carcinoma of the nasopharynx and larynx (non-metastatic cases). Better results were detected in radiological assessment post radiation therapy in laryngeal cancer cases and progression free survival in both treatment groups.

Keywords

Squamous cell carcinomas / Concurrent chemoradiation / Laryngeal & nasopharyngeal cancers

References

[1] Byakodi R, Byakodi S, Hiremath S, et al. Oral cancer in India: an epidemiologic and clinical review. J Community Health. 2012; 37: 316-319. PMid: 21786206. https://doi.org/10.1007/s10900-011-9447-6

[2] Pelucchi C, Gallus S, Garavello W, et al. Cancer risk associated with al-cohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res Health. 2006; 29: 193-198.

[3] Ansary-Moghaddam A, Huxley RR, Lam TH, et al. The risk of upper aero digestive tract cancer associated with smoking, with and without concurrent alcohol con-sumption. Mt Sinai J Med. 2009; 6: 392-403. PMid: 19642154. https://doi.org/10.1002/msj.20125

[4] Garneau JC, Bakst RL, Miles BA, et al. Hypo pharyngeal cancer: A state of the art review. Oral Oncol. 2018; 86: 244-250. PMid: 30409307. https://doi.org/10.1016/j.oraloncology.2018.09.025

[5] Sinha S. About Nasopharyngeal Cancer What Is Nasopharyngeal Cancer? American Cancer Society. 2018; 1-9.

[6] Pignon JP, Bourhis J, Domenge CO, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collab- orative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2009; 355: 949-955. https://doi.org/10.1016/S0140-6736(00)90011-4

[7] Machiels JP, Lambrecht M, Hanin FX, et al. Advances in the man- agement of squamous cell carcinoma of the head and neck. F1000 Prime Rep. 2014; 6: 6-44. PMid: 24991421. https://doi.org/10.12703/P6-44

[8] Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a compre- hensive analysis by tumour site. Radiotherapy Oncol. 2011, 100: 33-40. PMid: 21684027. https://doi.org/10.1016/j.radonc.2011.05.036

[9] Pointreau Y, Atean I, Fayette J, et al. Induction chemotherapy in head and neck cancer: a new paradigm. Anticancer Drugs. 2011; 22: 613-620. PMid: 21160420. https://doi.org/10.1097/CAD.0b013e3283425871

[10] Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian Journal of Psycho- logical Medicine. 2013; 35(2): 121. PMid: 24049221. https://doi.org/10.4103/0253-7176.116232

[11] Cohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 orN3 locally ad- vanced head and neck cancer. J Clin Oncol. 2014; 32: 2735-43. PMid: 25049329. https://doi.org/10.1200/JCO.2013.54.6309

[12] Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carci- noma of the head and neck: EHNS-ESMO-ESTRO Clinical Prac- tice Guidelines for diagnosis, treatment and follow-up. Ann On- col. 2010; 21 (Suppl 5): v184-v186. PMid: 20555077. https://doi.org/10.1093/annonc/mdq185

[13] Sher DJ, Posner MR, Tishler RB, et al. Relationship between radia- tion treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011; 81: e813-e818. PMid: 21300455. https://doi.org/10.1016/j.ijrobp.2010.12.005

[14] Brizel DM, Vokes EE. Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009; 19: 11-16. PMid: 19028340. https://doi.org/10.1016/j.semradonc.2008.09.003

[15] Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluo- rouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-704. PMid: 17960012. https://doi.org/10.1056/NEJMoa071028

[16] Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in lo- cally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27: 843-50. https://doi.org/10.1002/hed.20279PMid:16161069

[17] Cotter R, Blacksburg S, Carpenter T, et al. Does response to induc- tion chemotherapy (IC) predict locoregional control after concurrent chemoradiotherapy (CCRT) in locally advanced head and neck can- cer (LAHNC)? Oral Oncol. 2014; 50: e27-8. https://doi.org/10.1016/j.oraloncology.2014.03.002PMid:24680084

[18] Balermpas P, Bauer C, Fraunholz I, et al. Concomitant chemoradio- therapy versus induction chemotherapy followed by chemoradiother- apy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlenther Onkol. 2014; 190: 256-62. https://doi.org/10.1007/s00066-013-0509-9PMid:24413895

[19] Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without doc- etaxel for larynx preservation. J Natl Cancer Inst. 2009; 101: 498-506. https://doi.org/10.1093/jnci/djp007PMid:19318632

[20] Budach W, Bölke E, Kammers K, et al. Induction chemother- apy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squa- mous cell carcinoma of the head and neck (HNSCC): A meta- analysis of randomized trials. Radiotherapy and Oncology. 2016; 118: 238-243. https://doi.org/10.1016/j.radonc.2015.10.014PMid:26589131

[21] Zhang L, Jiang N, Shi Y, et al. Induction chemotherapy with con- current chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. Scientific Reports. 2015; 5: 10798. PMid: 26041604. https://doi.org/10.1038/srep10798

[22] Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014; 25: 216-25. PMid: 24256848. https://doi.org/10.1093/annonc/mdt461

[23] Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradio- therapy) versus concurrent chemoradiotherapy alone in locally ad- vanced head and neckcancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013; 14: 257-64. https://doi.org/10.1016/S1470-2045(13)70011-1

[24] Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemora- diotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally ad- vanced head and neck cancer: a phase II randomized study. Ann Oncol. 2010; 21: 1515-22. PMid: 20032123. https://doi.org/10.1093/annonc/mdp573

[25] Posner MR, Hershock DM, Blajman CR, et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 25(357): 1705-15. PMid: 17960013.https://doi.org/10.1056/NEJMoa070956

[26] Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin On- col. 2013; 31: 853-9. PMid: 23341517. https://doi.org/10.1200/JCO.2012.42.3988

[27] Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemother- apy and radiotherapy for organ preservation in advanced laryn- geal cancer. N Engl J Med. 2003; 349: 2091-8. PMid: 14645636. https://doi.org/10.1056/NEJMoa031317

[28] Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strate- gies to preserve the larynx in patients with locally advanced lar- ynx cancer. J Clin Oncol. 2013; 31: 845-52. PMid: 23182993. https://doi.org/10.1200/JCO.2012.43.6097

[29] Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017; 28: 2206-12. PMid: 28911070. https://doi.org/10.1093/annonc/mdx299